JP2025508406A5 - - Google Patents

Info

Publication number
JP2025508406A5
JP2025508406A5 JP2024548386A JP2024548386A JP2025508406A5 JP 2025508406 A5 JP2025508406 A5 JP 2025508406A5 JP 2024548386 A JP2024548386 A JP 2024548386A JP 2024548386 A JP2024548386 A JP 2024548386A JP 2025508406 A5 JP2025508406 A5 JP 2025508406A5
Authority
JP
Japan
Prior art keywords
treatment
compound
antidepressant
necessary
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508406A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/013098 external-priority patent/WO2023158668A1/en
Publication of JP2025508406A publication Critical patent/JP2025508406A/ja
Publication of JP2025508406A5 publication Critical patent/JP2025508406A5/ja
Pending legal-status Critical Current

Links

JP2024548386A 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド Pending JP2025508406A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US63/310,581 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US63/337,828 2022-05-03
US202363482200P 2023-01-30 2023-01-30
US63/482,200 2023-01-30
PCT/US2023/013098 WO2023158668A1 (en) 2022-02-16 2023-02-15 Neuroactive steroids for treatment of cns-related disorders

Publications (2)

Publication Number Publication Date
JP2025508406A JP2025508406A (ja) 2025-03-26
JP2025508406A5 true JP2025508406A5 (cg-RX-API-DMAC7.html) 2026-02-25

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548386A Pending JP2025508406A (ja) 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド

Country Status (11)

Country Link
US (1) US20250295674A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479032A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508406A (cg-RX-API-DMAC7.html)
KR (1) KR20240148425A (cg-RX-API-DMAC7.html)
CN (1) CN119072304A (cg-RX-API-DMAC7.html)
AU (1) AU2023220976A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252357A1 (cg-RX-API-DMAC7.html)
IL (1) IL315023A (cg-RX-API-DMAC7.html)
MX (1) MX2024009974A (cg-RX-API-DMAC7.html)
TW (1) TW202341995A (cg-RX-API-DMAC7.html)
WO (1) WO2023158668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2023012727A (es) * 2021-04-29 2023-11-08 Sage Therapeutics Inc Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Similar Documents

Publication Publication Date Title
JP6406713B2 (ja) 低用量薬剤によるうつ病および他の疾患の処置
JP2009511618A (ja) 中度から重度のむずむず脚症候群(rls)を治療するためのプラミペキソールの使用
JP7265990B2 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
JP2023100904A5 (cg-RX-API-DMAC7.html)
JP2006509751A5 (cg-RX-API-DMAC7.html)
JPH08208471A (ja) 薬物反応の増強作用
JP2009538331A (ja) 抑うつ障害のための治療
CN1308533A (zh) 具有抗抑郁效果的药物
JP2023143940A5 (cg-RX-API-DMAC7.html)
JP2021511365A5 (cg-RX-API-DMAC7.html)
JP2022519721A5 (cg-RX-API-DMAC7.html)
JP2022506113A5 (cg-RX-API-DMAC7.html)
Goldberg Antidepressant use in the elderly: current status of nefazodone, venlafaxine and moclobemide
JP2006506461A (ja) ミルナシプランのパルス型放出組成物
CN105848655B (zh) 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法
JP2025508051A5 (cg-RX-API-DMAC7.html)
EP2089022A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation
JP2021530568A5 (cg-RX-API-DMAC7.html)
WO2023112024A1 (en) Method of treating parkinson's disease
EA003546B1 (ru) Новые способы лечения нервных расстройств
JP2022521208A5 (cg-RX-API-DMAC7.html)
CN1468094A (zh) 含有依匹期汀及假麻黄碱的新药物组合物
JP2025500344A5 (cg-RX-API-DMAC7.html)
Pasternak Does tramadol have a place in the dental armamentarium? An atypical opioid in dental practice from the pharmacological perspective–Part I. General tramadol administration
CN113194950B (zh) 早泄(pe)的治疗和预防